The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Acerta Pharma/AstraZeneca; BeiGene; Janssen-Cilag; LOXO; Merck; TG Therapeutics
Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
 
Johannes Düll
Research Funding - MorphoSys; Regeneron
 
Kami J. Maddocks
Honoraria - ADC Therapeutics; BMS; Celgene; Genmab; Karyopharm Therapeutics; Kite, a Gilead company; MorphoSys; Pharmacyclics; Seagen
Research Funding - Bristol-Myers Squibb; Merck; Pharmacyclics
 
Eva Gonzalez-Barca
Consulting or Advisory Role - Abbvie; Celgene; EUSA Pharma; Gilead Sciences; Janssen; Kyowa Kirin
Speakers' Bureau - Abbvie; Janssen; Takeda
Travel, Accommodations, Expenses - Abbvie; Janssen; Roche
 
Wojciech Jurczak
No Relationships to Disclose
 
Anna Marina Liberati
Consulting or Advisory Role - SERVIER
Research Funding - Abbvie (Inst); Amgen (Inst); Archigen Biotech (Inst); beigene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); FibroGen (Inst); Incyte (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); MorphoSys (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Oncopeptides (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst); verastem (Inst)
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Celgene; IQvia; Novartis; Novartis; Roche; Sanofi; Takeda; Verastem
 
Aleš Obr
Honoraria - Janssen; Roche
Consulting or Advisory Role - Janssen
Speakers' Bureau - Roche
Travel, Accommodations, Expenses - Gilead Sciences; Janssen; Roche
 
Gianluca Gaidano
Honoraria - Abbvie; AstraZeneca; Janssen
Consulting or Advisory Role - Abbvie; AstraZeneca; Janssen
Speakers' Bureau - Abbvie; Janssen
Travel, Accommodations, Expenses - Janssen
 
Pau Abrisqueta
Honoraria - Abbvie; AstraZeneca; Celgene; Gilead Sciences; Janssen
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Janssen
Speakers' Bureau - Abbvie; AstraZeneca; Celgene; Gilead Sciences; Janssen
 
Marc André
Consulting or Advisory Role - BMSi; Takeda
Research Funding - Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Roche
 
Martin H. Dreyling
Consulting or Advisory Role - Acerta Pharma/AstraZeneca; Bayer/Vital; Beigene; Celgene/Jazz; Gilead Sciences; Janssen-Cilag; Novartis; Roche
Speakers' Bureau - Bayer Health; Celgene; Gilead Sciences; Janssen-Cilag; Roche Pharma AG
Research Funding - Abbvie (Inst); Celgene (Inst); Janssen-Cilag (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag; Roche Pharma AG
 
Tobias Menne
Honoraria - Janssen; Takeda
Consulting or Advisory Role - Amgen; Atara Biotherapeutics; Celgene; Daiichi Sankyo/Lilly; Kite/Gilead; Novartis; Pfizer
Speakers' Bureau - Kite/Gilead; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Janssen; Novartis
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen; Jazz Pharmaceuticals; Kite/Gilead
 
Maren Dirnberger-Hertweck
Employment - MorphoSys
 
Johannes Weirather
Employment - MorphoSys
 
Sumeet Vijay Ambarkhane
Employment - MorphoSys
Patents, Royalties, Other Intellectual Property - Patent under review
Travel, Accommodations, Expenses - MorphoSys
 
Gilles A. Salles
Honoraria - Abbvie; Celgene; Gilead Sciences; Janssen; MorphoSys; Novartis; Roche/Genentech
Consulting or Advisory Role - Alimera Sciences; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Epizyme; Genmab; Genmab; Gilead Sciences; Incyte; Janssen; Miltenyi Biotec; morphosys; Novartis; Roche/Genentech; Velosbio